STEMEDICA NEWS
PROMINENT HEALTH CARE EXECUTIVE JOINS STEMEDICA BOARD OF DIRECTORS
Anthony M. Marlon, MD was elected to the Stemedica Cell Technologies, Inc. (“Stemedica”) Board of Directors at the Company’s November 20th Board Meeting.
STEMEDICA PRESIDENT INVITED TO LECTURE AT THE UNIVERSITY OF OXFORD
Nikolai Tankovich, MD, Ph.D., President and Chief Medical Officer of Stemedica Cell Technologies, Inc. was invited to lecture at a multi-disciplinary seminar at the Centre for Science and Society at Trinity College, a constituent college of the University of Oxford, England.
STEMEDICA COMPLETES MEETING WITH THE FDA
Stemedica announced that it completed its pre-IND meeting with the U.S. Food and Drug Administration (FDA) regarding a proposed IND (Investigative New Drug) to evaluate the safety and efficacy of Stemedica's high potency proprietary allogeneic mesenchymal bone marrow-derived stem cells (adult human) as a treatment for ischemic stroke.
STEMEDICA’S PRESIDENT DELIVERS KEYNOTE ADDRESS AT SWISS-RUSSIAN FORUM
Dr. Nikolai Tankovich, President of Stemedica, delivered the keynote speech at the Crossing Visions Summit held in Moscow from September 14th – 16th. His presentation at a forum of top Russian and Swiss political, economic and business leaders featured advances in stem cell technology.
UNITED STATES PATENT AND TRADEMARK OFFICE PUBLISHES STEMEDICA'S PATENT APPLICATION FOR THE TREATMENT OF DIABETIC RETINOPATHY
Stemedica has filed a patent application with the United States Patent and Trademark Office ("USPTO") for a proprietary methodology in the treatment for Diabetic Retinopathy. The patent application was published by the USPTO on August 27th of this year.
DRIVEN BY 30 YEARS OF STEM CELL RESEARCH & SCIENTIFIC ADVANCEMENT
Stemedica's adult stem cell technology is based on thirty years of research and clinical experience conducted by researchers and clinicians in the former Soviet Union, Europe and the United States. The technology and scientific know-how advanced by these researchers and clinicians has either been acquired, or developed internally, by Stemedica.
To further substantiate these discoveries, and to continue to advance the science achieved by these leaders, Stemedica has established a laboratory and manufacturing facility in San Diego, California designed from the ground up to be fully cGMP (Current Good Manufacturing Practices) compliant. Additional laboratory and manufacturing facilities have been established in Moscow, Russia and in Seoul, Korea.
Stemedica has built an experienced team of international and domestic scientists and medical professionals that have been involved for the past four years in extensive research and stem cell product development including; a) confirming the safety, reliability and efficacy of the Company's science and technology; b) advancing the Company's protocols for isolating, expanding, processing, manufacturing and master banking of stem cells; and, c) refining Stemedica's methodologies and protocols used in clinical applications.
Stemedica continues to advance its adult stem cell technology for current pre-clinical and future clinical studies in the United States and for on-going pre-clinical and clinical studies internationally.
ABOUT ADULT STEM CELLS
What are adult stem cells?
Adult stem cells are cells which have not completely differentiated. They are found in all tissues of the human body. Adult stem cells, also known as somatic stem cells, have the potential to transform themselves into practically all other cell types. Adult stem cells are at the heart of Stemedica's technology and research.